Breaking News, Financial News

SK pharmteco Makes $100M Funding Commitment to Support Viral Vector Business

The company is also reaffirming its three-business-unit strategy, also including small molecules and peptides.

Author Image

By: Patrick Lavery

Content Marketing Editor

SK pharmteco is deploying $100 million to reinforce and expand capabilities across its viral vector business. Primarily, this concerns the company’s centers of excellence in King of Prussia, Pa., and Corbeil-Essones, France. As biopharma companies develop diverse pipelines—established therapeutics to advanced therapies—SK pharmteco says being a versatile CDMO is critical. SK pharmteco – A Three-Business-Unit Model The funding commitment, SK pharmteco says, both supports strategic initia...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters